The GLP is committed to full transparency. Download and review our 2019 Annual Report

Biotech firms Amfora, Corteva strike deal to produce CRISPR-edited crops to meet surging protein demand

| April 4, 2019
dfe a adb ed b
Image: REUTERS/Shamil Zhumatov
This article or excerpt is included in the GLP’s daily curated selection of ideologically diverse news, opinion and analysis of biotechnology innovation.

Amfora, a biotechnology company, announced it has reached a non-exclusive research and commercial license agreement with Corteva Agriscience, the agriculture division of DowDuPont, and the Broad Institute of MIT and Harvard. Through the agreement, Amfora will use intellectual property covering CRISPR-Cas9 and related gene editing tools to develop a portfolio of gene-edited crops with increased protein content.

Amfora is developing food and feed products with increased protein content to address growing consumer health and environmental concerns by improving crops most vital to global food security. This is crucial, because the world faces an increasingly significant shortfall in meeting the protein needs of its population due both to population growth and the increasing demand for foods high in protein….

Amfora’s first food products will be high-protein wheat and high-protein rice. Wheat is a food staple grown on 530 million acres globally and rice, a staple that feeds a majority of the world’s population, is grown on 400 million acres globally. Desirable wheat baking and pasta qualities are dependent on their high protein content. In many growing regions, wheat varieties and cultural practices do not meet the protein content requirement of consumers….

Read full, original article: Amfora enters gene editing licensing agreement with Corteva

Share via
News on human & agricultural genetics and biotechnology delivered to your inbox.
Optional. Mail on special occasions.
Send this to a friend